RemeGen Co., Ltd.

Equities

9995

CNE1000048G6

Biotechnology & Medical Research

Delayed Hong Kong S.E. Other stock markets 01:53:32 2024-04-18 am EDT			5-day change	1st Jan Change
26.85 ^HKD	-0.92%		-18.02%	-28.30%

Apr. 04	Remegen Gets US FDA Fast Track Designation for Primary Sjögren's Syndrome Medication	MT
Apr. 02	Remegen Co., Ltd. Announces FDA Grants Telitacicept Fast Track designation for Treatment of pSS	CI

Remegen Co., Ltd. Announces Change of Principal Place of Business in Hong Kong

March 26, 2021 at 10:09 am EDT

The board of directors of RemeGen Co., Ltd. announced that the Company's principal place of business in Hong Kong has been changed to 40th Floor, Dah Sing Financial Centre, No. 248 Queen's Road East, Wanchai, Hong Kong with effect from March 26, 2021.

Latest news about RemeGen Co., Ltd.

Remegen Gets US FDA Fast Track Designation for Primary Sjögren's Syndrome Medication	Apr. 04	MT
Remegen Co., Ltd. Announces FDA Grants Telitacicept Fast Track designation for Treatment of pSS	Apr. 02	CI
Remegen Plans A-Share Private Placement to Fund New Drug Development Project	Mar. 29	CI
RemeGen Co., Ltd. announced that it expects to receive CNY 2.549999941 billion in funding	Mar. 28	CI
RemeGen Co., Ltd.(XSSC:688331) added to FTSE All-World Index	Mar. 17	CI
RemeGen Co. Ltd. Presents Oral Presentation on Evaluation of its Proprietary Disitamab Vedotin for Cervical Cancer At ESGO 2024	Mar. 10	CI
RemeGen's 2023 Net Loss Widens; Revenue Jumps 40%	Feb. 26	MT
RemeGen Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 23	CI
RemeGen's Loss to Widen in 2023	Jan. 31	MT
RemeGen Co., Ltd. Provides Earnings Guidance for the Period from January 1, 2023 to December 31, 2023	Jan. 30	CI
RemeGen Buys Back HK$12 Million Worth of Hong Kong Shares	Jan. 23	MT
RemeGen Denies Rumors of Tight Cash Flow, Funding Hurdles	Jan. 17	MT
RemeGen's Rc88 Obtains FDA Fast Track Designation, Heralds New Hope for Ovarian Cancer Patients	Jan. 12	CI
RemeGen Co., Ltd.'s Pioneering RC88 Receives IND Approval from US FDA for Platinum-Resistant Recurrent Ovarian Cancer Treatment	Dec. 28	CI
RemeGen Gets Full Approval for Telitacicept	Nov. 22	MT
RemeGen Co., Ltd. Announces the Full Approval of. Telitacicept for. Systemic Lupus erythematosus by NMPA	Nov. 22	CI
RemeGen to Hike Annual Caps for Services Agreements	Nov. 20	MT
RemeGen Co., Ltd. to Present telitacicept Phase III Clinical Trial Results for Rheumatoid Arthritis Patients in A Late-Breaking Abstract Oral Presentation Session At the American College of Rheumatology	Nov. 15	CI
RemeGen Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-30	CI
Biotech Firm RemeGen Appoints CFO	23-09-29	MT
RemeGen Names CFO	23-09-28	MT
Remegen Co., Ltd. Appoints Tong Shaojing as the Chief Financial Officer	23-09-28	CI
Remegen Co., Ltd. Appoints Tong Shaojing as Joint Company Secretary	23-09-28	CI
RemeGen CFO Steps Down; Shares Tumble 5% in Shanghai	23-09-04	MT
RemeGen Co., Ltd. Announces Resignation of Li Jia as Joint Company Secretary	23-09-04	CI

Chart RemeGen Co., Ltd.

Duration

Period

More charts

Company Profile

RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of innovative biopharmaceuticals. The Company is mainly engaged in the discovery, development and commercialization of therapeutic antibody drugs such as antibody drug conjugates (ADCs), antibody fusion proteins, monoclonal antibodies and bispecific antibodies. The Company's main products include tetacept (RC18), veldicitumab (RC48) and dual-target fusion protein (RC28). The Company's products are mainly used to treat major diseases such as autoimmune diseases, oncology and ophthalmology. The Company mainly conducts its businesses in the domestic market.

Sector

Biotechnology & Medical Research

Calendar

2024-04-24 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for RemeGen Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

25.05 CNY

Average target price

39.92 CNY

Spread / Average Target

+59.36%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
REMEGEN CO., LTD.	-28.30%	3.09B
VERTEX PHARMACEUTICALS INCORPORATED	-3.39%	102B
REGENERON PHARMACEUTICALS, INC.	+2.61%	96.84B
ARGENX SE	-1.02%	21.48B
BIONTECH SE	-18.14%	20.82B
GENMAB A/S	-6.87%	18.6B
WUXI APPTEC CO., LTD.	-40.70%	16.81B
BEIGENE, LTD.	-26.89%	13.78B
NEUROCRINE BIOSCIENCES, INC.	+1.12%	13.4B
SAREPTA THERAPEUTICS, INC.	+22.25%	11.06B

Bio Therapeutic Drugs